<DOC>
	<DOCNO>NCT01670149</DOCNO>
	<brief_summary>Clostridium difficile associate diarrhoea important cause morbidity patient treat antibiotic , especially hospital . Clinical relapse occur 30 % initially successful treatment colitis . Preliminary report suggest Rifaximin , poorly absorb antibiotic use treat traveller diarrhoea prevent relapse . We plan carry randomised placebo control trial test hypothesis Rifaximin give reduce dose 4 week successful treatment reduce relapse rate .</brief_summary>
	<brief_title>Rifaximin Preventing Relapse Clostridium Associated Diarrhoea</brief_title>
	<detailed_description>Aims ) To examine efficacy follow-on course Rifaximin give successful initial course standard treatment , prevention relapse C. difficile associate diarrhoea ( CDAD ) . ii ) To examine change faecal microbiota patient give Rifaximin v . Placebo . Treatment 4 week treatment Rifaximin Placebo tablet . Tapering dose start 2 x 200mg tablet three time day ( total = 1.2g per day ) 1st 2 week , reduce 1 x 200mg tablet three time day ( total = 0.6g per day ) 2nd 2 week . Primary endpoint : The difference % relapse Rifaximin placebo 12 week</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Inclusion criterion : 1 . Men / Women age 18 ( We also include adult lack mental capacity legal representative ) 2 . Successful treatment clinically diagnose CDAD use standard therapy ( metronidazole vancomycin give accord standard local hospital guideline ) . Exclusion criterion : 1 . Woman child bear potential willing use least one highly effective contraceptive method throughout study 2 . Male spouse/partner child bear potential willing use condom 3 . Pregnant breast feed 4 . Unable swallow tablet 5 . Life expectancy &lt; 4 week 6 . Hypersensitivity active substance , rifamycin ( e.g . rifampicin rifabutin ) excipients ( Tablet core : Sodium starch glycolate type A , glycerol distearate , colloidal anhydrous , silica , talc microcrystalline cellulose . Tablet coating : hypromellose , titanium dioxide ( E171 ) , disodium edentate , propylene glycol red iron oxide E172 ) 7 . &gt; 5 day post standard therapy ( metronidazole vancomycin ) clinically diagnose CDAD 8 . Taking ciclosporin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>Diarrhoea</keyword>
	<keyword>Rifaximin</keyword>
</DOC>